GHK-Cu vs Melanotan 1
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of GHK-Cu and Melanotan 1 (also searched as Melanotan 1 vs GHK-Cu) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
GHK-Cu centers on skin, while Melanotan 1 leans toward skin. On indexed research, GHK-Cu is ahead (GHK-Cu: 5 studies, Preclinical; Melanotan 1: 4, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •GHK-Cu is strongest for skin; Melanotan 1 for skin.
- •Evidence: GHK-Cu Preclinical (5 studies) vs Melanotan 1 Preclinical (4).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Copper Peptide | Skin Regeneration & Anti-Aging Compound
GHK-Cu vs Melanotan 1: side-by-side
| Metric | GHK-Cu | Melanotan 1 |
|---|---|---|
| Class | Skin | — |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Preclinical | Preclinical |
| Studies indexed | 5 | 4 |
| Research level | Well Studied | — |
| Strongest effect | Skin & aesthetics | Skin & aesthetics |
| Healing & recovery | 4.0▲ | 2.0 |
| Muscle & body comp | 1.0▲ | 0.0 |
| Metabolic & appetite | 3.0▲ | 1.0 |
| Neuro & mood | 2.0 | 3.0▲ |
| Sleep & circadian | 1.0▲ | 0.0 |
| Inflammation & immune | 4.0▲ | 2.0 |
| Skin & aesthetics | 5.0▲ | 5.0▲ |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | GHK-Cu | Melanotan 1 |
|---|---|---|
| Mechanism | Copper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signaling | Melanocortin-receptor agonist |
| Route | Topical / subcutaneous | Subcutaneous injection (research use) |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is GHK-Cu?
Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.
Full GHK-Cu profile, mechanism & studies →What is Melanotan 1?
### Melanotan 1 Summary Melanotan 1, also known as afamelanotide, is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH) that primarily acts as a melanocortin receptor agonist. It has been investigated for its potential applications in enhancing skin pigmentation and its role in various therapeutic contexts, including neuroprotection and cancer research.
Full Melanotan 1 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | GHK-Cu | 4.0/5 effect signal |
| Muscle | GHK-Cu | 1.0/5 effect signal |
| Metabolic | GHK-Cu | 3.0/5 effect signal |
| Neuro | Melanotan 1 | 3.0/5 effect signal |
| Sleep | GHK-Cu | 1.0/5 effect signal |
| Inflammation | GHK-Cu | 4.0/5 effect signal |
| Skin | Even | Both ~5.0/5 |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack GHK-Cu and Melanotan 1?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
GHK-Cu vs Melanotan 1: side effects
- improved skin texture18
- localized irritation5
- transient tingling4
- gi upset1
- headache1
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
GHK-Cu has 5 approved studies indexed (Preclinical), and Melanotan 1 has 4 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is GHK-Cu or Melanotan 1 better?
It depends on your goal. GHK-Cu is strongest for skin; Melanotan 1 for skin. GHK-Cu has more indexed studies (5). See the goal-by-goal breakdown above.
Is GHK-Cu or Melanotan 1 better for weight loss?
GHK-Cu shows the stronger metabolic & appetite profile (3.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Is GHK-Cu or Melanotan 1 better for muscle?
GHK-Cu leads on the muscle & body-composition axis (1.0/5).
Which has more research, GHK-Cu or Melanotan 1?
GHK-Cu has 5 approved studies indexed (Preclinical); Melanotan 1 has 4 (Preclinical). Higher counts mean more to read, not proven superiority.
Can you stack GHK-Cu and Melanotan 1?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of GHK-Cu vs Melanotan 1?
GHK-Cu: community-reported improved skin texture, localized irritation, transient tingling. Melanotan 1: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is GHK-Cu or Melanotan 1 FDA-approved?
GHK-Cu is a research-use compound and is not FDA-approved. Melanotan 1 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Melanotan 1 better than GHK-Cu?
For skin, Melanotan 1 has the edge; for skin, GHK-Cu does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
GHK-Cu and Melanotan 1 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.